News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation
Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer’s disease, including DNA damage and inflammation. …
Read at ScienceDaily →The hidden math of Alzheimer's could point to new treatments
Mathematics may hold unexpected clues to understanding Alzheimer’s disease. Scientists have developed a model showing how common metals like copper and zinc may influence the buildup of proteins associated with the disease, while also exploring possible ways to stop…
Read at ScienceDaily → Archived copy (12 Oct 2026), Internet ArchiveNew Alzheimer's drug repairs DNA damage and reduces brain inflammation
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation…
Read at ScienceDaily → Archived copy (17 Jul 2026), Internet ArchiveScientists reprogram brain immune cells to fight Alzheimer’s
A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.
Read at ScienceDaily →Scientists found a new Alzheimer’s trigger and a drug that stops it
Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cell loss, reduced Alzheimer’s-related changes, and even appeared to promote healthier aging.
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveScientists say we’ve been treating Alzheimer’s all wrong
Alzheimer’s isn’t just one problem—it’s a tangled mix of biology, aging, and overall health. That’s why drugs targeting a single factor have fallen short, even as new treatments show modest benefits. …
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveScientists finally reveal how this Alzheimer’s drug really works
A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the Fc fragment. …
Follow new items in a feed reader: Atom feed.